Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

DLBCL gene expression classifier links subtypes to treatment response

LGsig uses transcriptional and genetic signals to classify diffuse large B-cell lymphoma and refine prediction of benefit from pola-R-CHP.

By Dr. Revathy Mohan V.R., MBBS · Oct 20, 2026 · 5 min read

Oncology·JCO

Perioperative Durvalumab Sustains EFS Benefit in Resectable NSCLC

Updated AEGEAN results show durable event-free survival benefit with perioperative durvalumab in resectable non-small cell lung cancer.

Oct 20, 2026

Oncology·JCO

Cancer Survivorship Care Still Struggles With Transition After 20 Years

A JCO commentary revisits cancer survivorship care and the persistent failures in moving patients from treatment to long-term…

Oct 20, 2026

Oncology·JCO

DEEPER Trial: Cetuximab Regimen Shows Survival Signal in Left-Sided mCRC

Final DEEPER analysis found no overall survival difference in the full cohort, but cetuximab improved PFS in left-sided…

Oct 20, 2026

Oncology·JCO

Hypofractionated Salvage Radiotherapy Matches Standard RT After Prostatectomy

Phase III trial found hypofractionated salvage radiotherapy after prostatectomy matched standard RT for biochemical control, with more GI…

Oct 20, 2026

Oncology·JCO

ctDNA Methylation Surveillance Boosts Curative Recurrence Treatment in Colorectal Cancer

A phase III trial found ctDNA methylation surveillance doubled curative-intent recurrence treatment in nonmetastatic colorectal cancer after surgery.

Oct 20, 2026

Oncology·JCO

ASCO Living Guideline Updates Therapy for HR-Positive HER2-Negative Breast Cancer

ASCO’s 2026 living guideline reinforces endocrine therapy as the backbone of stage I-III HR-positive, HER2-negative breast cancer care.

Oct 20, 2026

Oncology·JCO

Tisagenlecleucel Shows Durable 5-Year Survival in Pediatric ALL

Five-year follow-up from ELIANA shows durable relapse-free and overall survival with tisagenlecleucel in heavily pretreated pediatric and young…

Oct 20, 2026

Oncology·JCO

Durvalumab Plus Radiation Improves PFS in Inoperable NSCLC Without cCRT

In cCRT-ineligible locally advanced NSCLC, durvalumab with definitive radiation met a phase II PFS target and showed signals…

Oct 20, 2026

Oncology·JCO

Avatrombopag Improved Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers

In ACT-GI, avatrombopag corrected persistent chemotherapy-induced thrombocytopenia and prevented recurrence better than placebo in GI cancer patients.

Oct 20, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.